 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Vericel Corporation (VCEL) is a commercial-stage biopharmaceutical company.
The firm researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets.
It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
On February 26th, Vericel Corproation reported 4th Quarter December 2018 earnings of $0.11 per share on revenue of $31.3 million. The consensus earnings estimate was $0.05 per share on revenue of $29.2 million.
The company said it expects 2019 revenue of $108.0 million to $112.0 million. The current consensus estimate is revenue of $109.9 million for the year ending December 31, 2019.
Shares are heading higher in an upward trading channel. Shares just moved above their 50-day moving average. Higher share prices are expected for this stock.
Entry Point: $18.40
Stop Loss: $17.40
Trading Range: $8.95 - $21.01
Target Price: $20.25
VCEL closed at $16.75
